64 results
Page 2 of 4
8-K
EX-10.1
qazfj n6v9wbbu
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.2
uo5nrxb 6tjhv4r
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-99.1
voshw6 wh
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
DEFA14A
xagezc9e1otvo6rd5zn
26 Apr 21
Additional proxy soliciting materials
4:22pm
8-K
EX-1.1
xpeqp9ooxwqeju570c6
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
8-K
EX-99.1
7y152qwkuho9r o710e
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
DEFA14A
nsebp pyugpy6paqr
20 May 20
Additional proxy soliciting materials
4:59pm
DEFA14A
k616aa8otfnwpclam2l9
21 Apr 20
Additional proxy soliciting materials
5:05pm
8-K
EX-1.1
q9jkyweoro6y58
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
8-K
EX-99.1
p11n 7g78egk5po
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am